Results 231 to 240 of about 53,392 (269)
Some of the next articles are maybe not open access.

Latent Tuberculosis Infection

New England Journal of Medicine, 2021
Susan E Dorman
exaly   +3 more sources

Early Therapy for Latent Tuberculosis Infection

American Journal of Epidemiology, 2001
Abstract The risk of developing active tuberculosis is highest within the first 2 years of infection. Therefore, an intervention that targets persons with recent infection, such as identifying contacts of active cases, could be particularly effective as an epidemic control measure.
Elad Ziv   +2 more
exaly   +3 more sources

Treatment of Latent Tuberculosis Infection

Annals of Internal Medicine, 2015
possible comparisons, 42 (40%) were compared directly. Compared with placebo, isoniazid for 6 months (odds ratio [OR], 0.64 [95% credible interval {CrI}, 0.48 to 0.83]) or 12 months or longer (OR, 0.52 [CrI, 0.41 to 0.66]), rifampicin for 3 to 4 months (OR, 0.41 [CrI, 0.18 to 0.86]), rifapentine-isoniazid (OR, 0.61 [CrI, 0.29 to 1.22]), and rifampicin ...
Dominik, Zenner   +3 more
  +7 more sources

Management of Latent Tuberculosis Infection

JAMA, 2023
This JAMA Insights Clinical Update examines treatment recommendations and therapy options among adults with latent tuberculosis infection.
Steven, Kim   +2 more
openaire   +2 more sources

Latent Tuberculosis Infection

Seminars in Respiratory and Critical Care Medicine, 2004
Latent tuberculosis infection (LTBI) is a clinical condition characterized by a positive tuberculin skin test in the absence of clinical or radiological signs of active tuberculosis disease. It has been estimated that one third of the world's population is latently infected with Mycobacterium tuberculosis and serves as an enormous reservoir for future ...
Eric, Nuermberger   +2 more
openaire   +2 more sources

Latent Mycobacterium tuberculosis Infection

New England Journal of Medicine, 2015
The natural history of tuberculosis begins with the inhalation of Mycobacterium tuberculosis organisms; a period of bacterial replication and dissemination ensues, followed by immunologic containment of viable bacilli. The result of this process is asymptomatic latent tuberculosis infection, which is defined as a state of persistent bacterial viability,
Getahun, Haileyesus   +3 more
openaire   +8 more sources

Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection

JAMA, 2005
Tuberculosis (TB) has emerged as a global public health epidemic. Despite decreasing numbers of cases in the United States since 1992, TB remains a serious public health problem among certain patient populations and is highly prevalent in many urban areas.
Henry M, Blumberg   +2 more
openaire   +2 more sources

Treatment of latent tuberculosis infection

Seminars in Respiratory Infections, 2003
Treatment of latent tuberculosis infection (LTBI) is considered an essential component of TB control programs in several industrialized countries and is being used in selected situations in developing countries. In 2000, the American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC) published new recommendations on the ...
openaire   +2 more sources

Treatment strategies for the latent tuberculosis infections

Journal of Mathematical Biology, 2023
This study investigates the dynamics of tuberculosis transmission through mathematical modeling, incorporating exogenous reinfections and different treatment approaches for latent tuberculosis infections. We examine three types of treatment rates: saturated, unsaturated, and mass screening-then-treatment.
Hui Cao, Baojun Song, Yicang Zhou
openaire   +2 more sources

Latent Tuberculosis Infection and BCG Vaccination

Journal of Midwifery & Women's Health, 2005
One third of the world's population is infected with Mycobacterium tuberculosis, and 5% to 10% of those infected will develop active disease. Identification and treatment of latent tuberculosis infection (LTBI) is an essential part of the public health strategy to control the spread of TB.
Lisa, Ross, Meredith, Goff
openaire   +2 more sources

Home - About - Disclaimer - Privacy